SANTA ROSA - September 1, 2011
Today, Osseon® Therapeutics, Inc. launched the Osseoflex®SN (steerable needle). Osseoflex SN is the newest in Osseon’s suite of minimally invasive products for treatment of spinal compression fractures.
The Osseoflex SN allows direct unipedicular access to the entire vertebral body. The Osseoplasty™ procedure offers unparalleled flexibility and control for percutaneous vertebral augmentation, cement delivery, and fracture stabilization, resulting in significant pain relief for most patients within the same day.
“Osseoflex SN is the next generation of steerable, minimally invasive cement delivery devices for the treatment of osteoporosis and related bone diseases and injuries. Our technology for vertebral compression fracture treatment offers increased precision, less operating time for physicians and decreased risk for patients,” said John Stalcup, Ph.D., Osseon’s CEO and President.
Osseon Therapeutics currently markets Osseoflex®SN (steerable needle), Osseoperm® (bone cement), Osseoflex®DR (steerable bone drill), Osseoflex®BT (steerable bone tamp), and Osseoflex®Access (bone access kit). Together, Osseon’s suite of products provides groundbreaking biomedical devices for physicians who treat vertebral compression fractures due to osteoporosis, myeloma, and acute osteo-traumatic injuries.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company’s groundbreaking technology and delivery systems provide efficacy and safety competitive with all other commercial solutions, while delivering superior efficiency and cost. By improving the treatment of compression fractures within the entire thoracic and lumbar spine, Osseon offers alternative solutions to symptomatic patients as well as to the physicians and medical facilities that treat them. Osseon’s products have received both FDA clearance and the CE Mark for product distribution in the United States and the European Union.
For more information, visit our website at www.osseon.com.
CONTACT: Michael Bivens, Director of Business Development, Osseon Therapeutics, 707.636.5953